These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 7908126

  • 1. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
    Zadow B, Schmidt WJ.
    Naunyn Schmiedebergs Arch Pharmacol; 1994 Jan; 349(1):61-5. PubMed ID: 7908126
    [Abstract] [Full Text] [Related]

  • 2. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.
    Hauber W, Andersen R.
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):486-90. PubMed ID: 8114947
    [Abstract] [Full Text] [Related]

  • 3. The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849.
    Hauber W, Waldenmeier MT.
    Eur J Pharmacol; 1994 May 02; 256(3):339-42. PubMed ID: 7913894
    [Abstract] [Full Text] [Related]

  • 4. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
    Maj J, Rogóz Z, Skuza G, Kołodziejczyk K.
    Pol J Pharmacol; 1995 May 02; 47(6):501-7. PubMed ID: 8868372
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil.
    Löscher W, Hönack D.
    Br J Pharmacol; 1994 Dec 02; 113(4):1349-57. PubMed ID: 7889291
    [Abstract] [Full Text] [Related]

  • 8. The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization.
    Riedinger K, Kulak A, Schmidt WJ, von Ameln-Mayerhofer A.
    Behav Brain Res; 2011 Mar 17; 218(1):194-9. PubMed ID: 21130808
    [Abstract] [Full Text] [Related]

  • 9. Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice.
    Vanover KE.
    Psychopharmacology (Berl); 1998 Mar 17; 136(2):123-31. PubMed ID: 9551768
    [Abstract] [Full Text] [Related]

  • 10. N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4- isoxazoleproprionate (AMPA) glutamate-receptor antagonists have different interactions with the discriminative stimuli of abused drugs.
    Jackson A, Brown G, Stephens DN.
    Psychopharmacology (Berl); 1996 Dec 17; 128(3):320-7. PubMed ID: 8972552
    [Abstract] [Full Text] [Related]

  • 11. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
    Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN.
    Exp Neurol; 2005 Dec 17; 196(2):422-9. PubMed ID: 16203001
    [Abstract] [Full Text] [Related]

  • 12. Blocking the trigeminal EPSP in rat abducens motoneurons in vivo with the AMPA antagonists NBQX and GYKI 53655.
    Ruiz A, Durand J.
    Brain Res Bull; 2000 May 15; 52(2):99-107. PubMed ID: 10808079
    [Abstract] [Full Text] [Related]

  • 13. Allosteric interactions between cyclothiazide and AMPA/kainate receptor antagonists.
    Yamada KA, Turetsky DM.
    Br J Pharmacol; 1996 Apr 15; 117(8):1663-72. PubMed ID: 8732274
    [Abstract] [Full Text] [Related]

  • 14. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists.
    Papa SM, Engber TM, Boldry RC, Chase TN.
    Eur J Pharmacol; 1993 Mar 02; 232(2-3):247-53. PubMed ID: 8385618
    [Abstract] [Full Text] [Related]

  • 15. A comparison of intravenous NBQX and GYKI 53655 as AMPA antagonists in the rat spinal cord.
    Chizh BA, Cumberbatch MJ, Headley PM.
    Br J Pharmacol; 1994 Jul 02; 112(3):843-6. PubMed ID: 7522860
    [Abstract] [Full Text] [Related]

  • 16. Disruption of operant oral self-administration of ethanol, sucrose, and saccharin by the AMPA/kainate antagonist, NBQX, but not the AMPA antagonist, GYKI 52466.
    Stephens DN, Brown G.
    Alcohol Clin Exp Res; 1999 Dec 02; 23(12):1914-20. PubMed ID: 10630610
    [Abstract] [Full Text] [Related]

  • 17. AMPA receptor antagonists, GYKI 52466 and NBQX, do not block the induction of long-term potentiation at therapeutically relevant concentrations.
    Kapus G, Székely JI, Durand J, Ruiz A, Tarnawa I.
    Brain Res Bull; 2000 Aug 02; 52(6):511-7. PubMed ID: 10974490
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Some behavioral effects of CNQX AND NBQX, AMPA receptor antagonists.
    Maj J, Rogóz Z, Skuza G, Jaros T.
    Pol J Pharmacol; 1995 Aug 02; 47(4):269-77. PubMed ID: 8616504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.